NEW YORK, May 8, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Express Scripts Holding Company (NASDAQ: ESRX), Humana Inc. (NYSE: HUM), Endo International Plc (NASDAQ: ENDP), Incyte Corporation (NASDAQ: INCY) and Citrix Systems, Inc. (NASDAQ: CTXS). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2197-100free.
Express Scripts Holding Company Analyst Notes
On April 29, 2014, Express Scripts Holding Company (Express Scripts) released its Q1 2014 financial results and disappointed the street with its weaker-than-expected performance as well as reduced earnings guidance for full-year 2014. The Company's net income in Q1 2014 declined to $328.3 million, or $0.42 per diluted share, from $373.0 million, or $0.45 per diluted share, in Q1 2013. Express Scripts' adjusted diluted EPS stood at $0.99, which missed the Reuters' analysts' average forecasts by 2 cents. Express Scripts stated that its performance was affected by lower adjusted prescription volume due to severe winter weather, later than expected enrollment in public exchanges and lower net new healthcare reform lives. Revenues also fell 9.0% YoY to $23.7 billion. The Company now expects adjusted EPS of $4.82 to $4.94 for full-year 2014, down from its prior forecast of $4.88 to $5.00. On April 30, 2014, the stock fell 6.24% to $66.58. The full analyst notes on Express Scripts are available to download free of charge at:
http://www.analystsreview.com/2197-ESRX-08May2014.pdf
Humana Inc. Analyst Notes
On April 30, 2014, Humana Inc. (Humana) announced that its Board of Directors has declared a cash dividend to stockholders of $0.28 per share. Humana informed that the cash dividend is payable on July 25, 2014 to stockholders of record as of the close of business on June 30, 2014. The full analyst notes on Humana are available to download free of charge at:
http://www.analystsreview.com/2197-HUM-08May2014.pdf
Endo International Plc Analyst Notes
On May 1, 2014, Endo International Plc (Endo) announced financial results for Q1 2014. The Company reported a net loss of $436.9 million in Q1 2014, as compared to net income of $15.3 million in Q1 2013. Endo stated that net loss reported for the period is primarily attributable to one-time charge of $625 million for settlement of all the approximately 20,000 claims, mostly related to vaginal mesh cases. The adjusted diluted EPS of the Company came in at $0.92, down 15.6% YoY. On average, analysts polled by Reuters expected the Company to post adjusted earnings of $0.84 per share. Endo's revenues in Q1 2014 fell 9.7% YoY to $594.6 million. Looking ahead, the Company expects full-year 2014 revenues to be in the range of $2.55 billion and $2.64 billion; and the full-year 2014 adjusted diluted EPS is expected to be between $3.60 and $3.85. The full analyst notes on Endo are available to download free of charge at:
http://www.analystsreview.com/2197-ENDP-08May2014.pdf
Incyte Corporation Analyst Notes
On May 1, 2014, Incyte Corporation (Incyte) reported Q1 2014 financial results. Incyte stated that revenues during the quarter increased 26.3% YoY to $89.8 million, helped mainly by robust growth in sales of Jakafi (ruxolitinib). Incyte reported that net loss widened to $34.0 million or $0.21 per share in Q1 2014 from $15.7 million or $0.12 per share in Q1 2013, primarily due to the Company's broad investment in its clinical pipeline and additional costs related to the commercialization of Jakafi in myelofibrosis and preparation for the anticipated launch in polycythemia vera. On average, analysts polled by Reuters expected the Company to report a loss of $0.18 per share, with revenues at $97.2 million. The full analyst notes on Incyte are available to download free of charge at:
http://www.analystsreview.com/2197-INCY-08May2014.pdf
Citrix Systems, Inc. Analyst Notes
On April 28, 2014, Citrix Systems Inc. (Citrix) announced important improvements to Podio -- the productivity and work management tool in its mobile workspace portfolio. Citrix claimed that the reformed look and feel of Podio enables users to dramatically reinvent the way they organize their daily work. According to the Company, these enhancements comprise of a quicker user interface, new in-built drag-and-drop design and stronger ways to automate and link tasks within Podio. Kasper Hulthin, Citrix Podio, Co-Founder and Product & Marketing Lead, said, "From the start, we wanted to set Podio apart from other project management and collaboration tools by making it more user-friendly and, crucially, more customizable. With the Creator release, we're one step closer to our vision of giving every user - whether they're a web designer, creative writer or media buyer - complete control of the way they get work done." The full analyst notes on Citrix are available to download free of charge at:
http://www.analystsreview.com/2197-CTXS-08May2014.pdf
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
EDITOR'S NOTES:
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
